$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414065473 Filed on November 06, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.200M	$2.740M	$2.970M
YoY Change	7.74%	28.04%	10.82%
% of Gross Profit
Research & Development	$1.770M	$1.609M	$6.550M
YoY Change	-72.98%	-69.99%	16.55%
% of Gross Profit
Depreciation & Amortization	$0.00	$6.000K	$10.00K
YoY Change	-100.0%
% of Gross Profit
Operating Expenses	$4.960M	$4.346M	$9.520M
YoY Change	-47.9%	-18.93%	14.7%
Operating Profit	-$4.961M	-$4.346M	-$9.524M
YoY Change	-47.91%	-42.08%	14.76%
Interest Expense	$1.250M	$121.0K	-$270.0K
YoY Change	-562.96%	-75.46%	-27.03%
% of Operating Profit
Other Income/Expense, Net		-$246.0K
YoY Change
Pretax Income	-$3.710M	-$4.590M	-$9.800M
YoY Change	-62.14%	-41.38%	13.16%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.713M	-$4.592M	-$9.798M
YoY Change	-62.1%	-41.37%	13.09%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$99.30K	-$127.4K	-$274.4K
COMMON SHARES
Basic Shares Outstanding	44.31M shares	44.31M shares	35.61M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$73.92M	$71.60M	$99.50M
YoY Change	-25.71%	-32.64%	147.51%
Cash & Equivalents	$49.76M	$71.59M	$99.52M
Short-Term Investments	$24.16M	$100.0K
Other Short-Term Assets	$700.0K	$400.0K	$500.0K
YoY Change	40.0%	33.33%	25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$70.46M	$72.07M	$100.0M
YoY Change	-29.56%	-32.36%	146.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$52.00K	$58.00K	$447.0K
YoY Change	-88.37%	-87.17%	776.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$250.0K	$300.0K
YoY Change
Other Assets	$64.00K	$181.0K	$104.0K
YoY Change	-38.46%	66.06%	-70.2%
Total Long-Term Assets	$18.86M	$15.94M	$551.0K
YoY Change	3323.23%	2740.46%	37.75%
TOTAL ASSETS
Total Short-Term Assets	$70.46M	$72.07M	$100.0M
Total Long-Term Assets	$18.86M	$15.94M	$551.0K
Total Assets	$89.33M	$88.01M	$100.6M
YoY Change	-11.19%	-17.83%	145.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$366.0K	$333.0K	$468.0K
YoY Change	-21.79%	-70.11%	-54.52%
Accrued Expenses	$3.683M	$3.200M	$4.430M
YoY Change	-16.86%	36.05%	102.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$6.200M
YoY Change		-100.0%	244.44%
Total Short-Term Liabilities	$4.077M	$3.557M	$11.21M
YoY Change	-63.63%	-63.12%	118.43%
LONG-TERM LIABILITIES
Long-Term Debt	$14.00M	$14.00M	$7.000M
YoY Change	100.0%	66.67%	-43.55%
Other Long-Term Liabilities	$722.0K	$793.0K	$1.077M
YoY Change	-32.96%	-48.54%	-25.26%
Total Long-Term Liabilities	$722.0K	$1.181M	$1.077M
YoY Change	-32.96%	-23.36%	-25.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.077M	$3.557M	$11.21M
Total Long-Term Liabilities	$722.0K	$1.181M	$1.077M
Total Liabilities	$18.80M	$18.75M	$19.30M
YoY Change	-2.6%	-4.32%	1.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.7M	-$138.0M	-$121.3M
YoY Change	16.8%	23.73%	44.14%
Common Stock	$46.00K	$44.00K	$40.00K
YoY Change	15.0%	25.71%	66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$70.52M	$69.26M	$81.28M
YoY Change
Total Liabilities & Shareholders Equity	$89.33M	$88.01M	$100.6M
YoY Change	-11.19%	-17.83%	145.37%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$3.713M	-$4.592M	-$9.798M
YoY Change	-62.1%	-41.37%	13.09%
Depreciation, Depletion And Amortization	$0.00	$6.000K	$10.00K
YoY Change	-100.0%
Cash From Operating Activities	-$3.520M	-$2.720M	-$7.140M
YoY Change	-50.7%	-62.33%	0.56%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$150.0K
YoY Change	-100.0%	-100.0%	-400.0%
Acquisitions
YoY Change
Other Investing Activities	-$22.67M	-$50.00K	-$150.0K
YoY Change	15013.33%		-34.78%
Cash From Investing Activities	-$22.67M	-$50.00K	$0.00
YoY Change		-162.5%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.370M	-1.440M	390.0K
YoY Change	1020.51%	-103.16%	290.0%
NET CHANGE
Cash From Operating Activities	-3.520M	-2.720M	-7.140M
Cash From Investing Activities	-22.67M	-50.00K	0.000
Cash From Financing Activities	4.370M	-1.440M	390.0K
Net Change In Cash	-21.82M	-4.210M	-6.750M
YoY Change	223.26%	-110.97%	-7.28%
FREE CASH FLOW
Cash From Operating Activities	-$3.520M	-$2.720M	-$7.140M
Capital Expenditures	$0.00	$0.00	$150.0K
Free Cash Flow	-$3.520M	-$2.720M	-$7.290M
YoY Change	-51.71%	-62.74%	3.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	333000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71592000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 24.5pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.5pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 24.45pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 24.45pt"> <font style="FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, the valuation of its common stock (“Common Stock”) prior to the Company becoming public and Common Stock warrants, stock options, fair value of investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from our estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99521000	USD
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	52000	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	428000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	510000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	72072000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	100031000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	447000	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15446000	USD
CY2014Q3	us-gaap	Long Term Investments LongTermInvestments	250000	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	181000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104000	USD
CY2014Q3	us-gaap	Assets Assets	88007000	USD
CY2013Q4	us-gaap	Assets Assets	100582000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	468000	USD
CY2014Q3	us-gaap	Interest Payable Current InterestPayableCurrent	25000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	109000	USD
CY2014Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6203000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3557000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11210000	USD
CY2014Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	14009000	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	7017000	USD
CY2014Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1181000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1077000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	18747000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	19304000	USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	40000	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207231000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202580000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138015000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121342000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	69260000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	81278000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88007000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100582000	USD
CY2014Q1	us-gaap	Long Term Investments LongTermInvestments	250000	USD
	invest	Investment Options Expiration Date InvestmentOptionsExpirationDate	2014-09-30
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-400000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27360000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28664822	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35977355	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32634683	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5228805	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8889050	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5326424	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9164131	shares
	us-gaap	Interest Expense Debt InterestExpenseDebt	1500000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	1200000	USD
CY2013Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	493000	USD
CY2014Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	121000	USD
	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	unpaid principal amount of each advance shall bear interest at a rate per annum equal to the rate payable on the Company’s money market account of 0.75% plus a margin of 150 basis points.
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	467000	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20000	USD
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	129767	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	129767	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44312193	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39652950	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44312193	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39652950	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.84
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.28
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	632000	USD
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	450000	USD
CY2014Q3	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	285000	USD
CY2013Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	1502000	USD
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	651000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	351000	USD
CY2014Q3	cndo	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	758000	USD
CY2013Q4	cndo	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1245000	USD
CY2014Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	0	USD
CY2013Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	190000	USD
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	500000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	500000	USD
CY2014Q3	cndo	Lease Impairment Current LeaseImpairmentCurrent	165000	USD
CY2013Q4	cndo	Lease Impairment Current LeaseImpairmentCurrent	0	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	208000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	192000	USD
CY2014Q3	cndo	Debt Instrument Term Charges DebtInstrumentTermCharges	0	USD
CY2013Q4	cndo	Debt Instrument Term Charges DebtInstrumentTermCharges	398000	USD
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	793000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	679000	USD
CY2014Q3	cndo	Lease Impairment Noncurrent LeaseImpairmentNoncurrent	268000	USD
CY2013Q4	cndo	Lease Impairment Noncurrent LeaseImpairmentNoncurrent	0	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	300000	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	100500	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	114000	USD
CY2013Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	34500	USD
CY2014Q3	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	39000	USD
	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	100000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	400000	USD
CY2014Q3	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	250000	USD
CY2014Q3	invest	Investment Options Expiration Date InvestmentOptionsExpirationDate	2014-09-30
	us-gaap	Share Based Compensation ShareBasedCompensation	4072000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4082000	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1266000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1484000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3117777000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	323412000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	630000000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2164365000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2164365000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1647698000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.31
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14009000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	15446000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	88769000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-14527000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	66068000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	345000	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.69
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.40
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M10D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M20D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M20D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y4M10D
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19130000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8473000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5361000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1609000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7126000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7218000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2143000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2737000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26256000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15691000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7504000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4346000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	350000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	517000	USD
CY2013Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	165000	USD
CY2014Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	168000	USD
	us-gaap	Interest Expense InterestExpense	1454000	USD
	us-gaap	Interest Expense InterestExpense	1206000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	493000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	121000	USD
	us-gaap	Professional Fees ProfessionalFees	32000	USD
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1500000	USD
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	16400000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P9M18D
	cndo	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	80705	shares
	cndo	Cash Less Exercise Of Warrants CashLessExerciseOfWarrants	158429	shares
	cndo	Warrants Exercise Price WarrantsExercisePrice	5.02
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	79000	USD
CY2014Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	40000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	400000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	555000	USD
	us-gaap	Depreciation Depreciation	11000	USD
	us-gaap	Depreciation Depreciation	17000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	723000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-114000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-3000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-84000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	252000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1366000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	0	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-398000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	0	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-75000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22514000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12807000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	187000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	250000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-187000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-595000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	90629000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	606000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1860000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	32000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	13655000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	15400000	USD
CY2014Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	1	pure
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-27929000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40199000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106267000	USD
	us-gaap	Interest Paid InterestPaid	1052000	USD
	us-gaap	Interest Paid InterestPaid	614000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	4000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	CORONADO BIOSCIENCES INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44312193	shares
CY2014Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	120000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	50000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	293000	USD
	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-293000	USD
CY2013Q3	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2014Q3	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-293000	USD
CY2014Q3	us-gaap	Prepaid Rent PrepaidRent	200000	USD
CY2014Q3	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	119000	USD

Files In Submission

Name	View Source	Status
0001144204-14-065473-index-headers.html	Edgar Link	pending
0001144204-14-065473-index.html	Edgar Link	pending
0001144204-14-065473.txt	Edgar Link	pending
0001144204-14-065473-xbrl.zip	Edgar Link	pending
cndo-20140930.xml	Edgar Link	completed
cndo-20140930.xsd	Edgar Link	pending
cndo-20140930_cal.xml	Edgar Link	unprocessable
cndo-20140930_def.xml	Edgar Link	unprocessable
cndo-20140930_lab.xml	Edgar Link	unprocessable
cndo-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v392450_10q.htm	Edgar Link	pending
v392450_ex31-1.htm	Edgar Link	pending
v392450_ex31-2.htm	Edgar Link	pending
v392450_ex32-1.htm	Edgar Link	pending
v392450_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2014 Q4 Form 10-Q Financial Statement

#000114420414065473 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2014 Q4 Form 10-Q Financial Statement

#000114420414065473 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio